Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

April 18, 2015 1:36 PM ET

Company Overview of Amsterdam Molecular Therapeutics (AMT) Holding N.V.

Executive Profile

Sander van Deventer M.D., Ph.D.

Co-Founder, Advisor, Member of Supervisory Board, Chairman of Remuneration Committee and Chairman of Nominating & Corporate Governance Committee, uniQure N.V.
AgeTotal Calculated CompensationThis person is connected to 8 Board Members in 8 different organizations across 9 different industries.

See Board Relationships


Dr. Sander van Deventer, M.D., Ph.D., is a Managing Partner at Forbion Capital Partners. Dr. van Deventer was a General Partner at Forbion Capital Partners. Dr. van Deventer serves as a Venture Partner at ABN AMRO Capital Benelux since 2004. He is a Co-Founder and Advisor at uniQure N.V. He served as Interim Chief Executive Officer at uniQure N.V. from February 2009 to October 2009. He served as a Venture Partner of AAC Capital Partners (ABN AMRO Capital) in 2004. He ...

Corporate Headquarters

Meibergdreef 61
Amsterdam, Noord-Holland 1105 BA


Phone: 31 20 566 7394
Fax: 31 20 566 9272

Board Members Memberships

Former Vice Chairman


University of Amsterdam
University of Amsterdam
University of Amsterdam

Other Affiliations

Annual Compensation

There is no Annual Compensation data available.

Stocks Options

There is no Stock Options data available.

Total Compensation

Total Annual Cash Compensation$13,000
Total Calculated Compensation$22,000

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup


There is no Competitor Compensation data available.

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Amsterdam Molecular Therapeutics (AMT) Holding N.V., please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at